ClariCore Optical Biopsy System Used in TRUS (Trans-Rectal Ultrasound)-Guided Prostrate Biopsy

Status unconfirmed · Not applicable

Conditions studied: Cellular Diagnosis, Prostate Cancer

In brief

The purpose of the study is to collect information on prostrate biopsy tissue for use in developing a method determining the difference in normal and cancerous prostrate tissue using the ClariCore System.

Key facts

Study ID

NCT02928640

Run by

Precision Biopsy, Inc.

People needed

200

Starts

2016-09-01

Expected to finish

2020-12-01

Last updated by the study team

2019-02-15

Who can join

Age: 22 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Patient scheduled for TRUS-guided prostrate biopsy with or without MR TRUS Fusion determined based on standard of care requirements
• Prostrate volume ≥ 20cc and height at least 22mm (at the area(s) to be biopsied) as verified by ultrasound or prostrate MRI
• Patient, or authorized representative signs a written Informed Consent form to participate in the study, prior to any study mandated determinations or procedure

You may not qualify if…

• Contraindications to TRUS prostrate biopsy
• Acute painful perianal disorder
• Surgical absence of a rectum or the presence of a rectal fistula
• Patients with contraindications to MRI (e.g., pacemaker, claustrophobia, etc.) (MR/TRUS only)
• --Patients with renal dysfunction are excluded due to their inability to undergo contrast enhanced MRI
• Previous prostrate surgeries
• Prior pelvic irradiation
• Active inflammatory bowel disease within the last 6 months
• Any condition, or history of illness or surgery that, in the opinion of the Investigator, might confound the results of the study or pose additional risks to the patient (e.g., significant cardiovascular conditions or allergies)
• Patient has systemic infection or evidence of any surgical site infection (superficial or organ space), including active urinary tract infection
• Bladder cancer (current or prior)
• Symptomatic acute prostatitis
• Actively taking blood thinning agents (with the exception of low dose aspirin [81 mg] Plavix, Coumadin, etc.) or severe comorbidity prohibiting halting of anticoagulation therapies or history of bleeding disorder (e.g., coagulopathy
• Any malignancy other than non-melanoma cell skin cancer, unless no evidence of disease for a minimum of 5 years
• Hormone therapy for locally advanced disease (except patients on 5-alpha reductase inhibitors to reduce the size of the prostrate)
• Neo-adjuvant hormonal therapy
• Salvage radical prostatectomy, i.e., patients having surgery due to failure of previous therapy (radiation, brachytherapy, cryotherapy, etc.)
• Patient has a compromised immune system or autoimmune disease (WBC < 4000 or > 20,000)
• Patient is not likely to comply with the follow-up evaluation schedule
• Patient is participating in a clinical trial of another investigational drug or device
• Patient is mentally incompetent or a prisoner

Where it is running

• The Urology Center of Colorado — Denver, Colorado, United States
• Johns Hopkins Brady Urological Institute- The Johns Hopkins Hospital — Baltimore, Maryland, United States
• Comprehensive Urology — Royal Oak, Michigan, United States
• Associated Professionals of New York, PLLC — Syracuse, New York, United States
• Carolina Urologic Research Center — Myrtle Beach, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.